Press

PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted

Sep 19 • 2 min read

PsyBio Therapeutics Corp. ( TSXV: PSYB | OTCQB: PSYBF), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the formal acceptance by the United States Patent and Trademark Office of its latest U.S. PCT (Non-Provisional) Patent Application. “PsyBio continues to…

Core One Labs’ Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential

Sep 19 • 3 min read

Core One Labs Inc. (CSE:COOL | OTCQB:CLABF | Frankfurt:LD6, WKN:A3CSSU) is pleased to announce that following the receipt of very positive results during phase one pre-clinical development studies conducted by its wholly owned subsidiary Akome Biotech Ltd., and their research partners, relating to the neuroactivities of its selected bioactive-compounds. The results obtained from Akome and its…

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

Sep 19 • 2 min read

Braxia Scientific Corp., (CSE: BRAXO | TC: BRAXF | FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters. The Canadian Settlement contemplates a cash payment of CDN $1.9 million,…

Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants

Sep 19 • 1 min read

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has decided to issue 122,160 common shares in the capital of the Company (“Shares”) in lieu of payment of $10,000, monthly, starting May 1st 2022,…

Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™

Sep 19 • 2 min read

Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application No. 17/546,880 filed on December 9, 2021 and titled Complexing Agent Salt Formulations of Pharmaceutical Compounds. Bexson’s formulation platform, branded…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435